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In the last years, there has been an increasing incidence of hepatocellular carcinoma 1 (HCC). The majority of these tumors develop in patients who have liver cirrhosis. The development of HCC has an impact in the natural history of liver disease. In a systematic review of studies that evaluated the natural history of cirrhosis, the presence of HCC was identified as a predictor of death in 66% of the studies in patients with decompensated cirrhosis that included this variable in their analysis 2 . However, an increasing variety of therapeutic options are available for patients with HCC 3 . Many of these options have survival benefit, so it is conceivable that these patients with HCC with longer survival, will have greater chances of developing complications of end-stage liver disease.
Variceal bleeding is one of the complications that characterize decompensated cirrhosis. In the last 30 years there has been a substantial improvement in the survival of patients with variceal bleeding due to the use of vasoactive drugs, the introduction of endoscopic band ligation and the use of antibiotic prophylaxis 4, 5 . Presently, further efforts are targeted at developing individualized therapeutic strategies in order to adjust the approach to the risk the patient has 6, 7 .
Several prognostic studies have identified the presence of HCC as a negative prognostic factor in variceal bleeding 5, 8, 9 . However, many studies in the context of variceal bleeding were performed at times when the incidence of HCC was much lower 10, 11 . Furthermore, most observational and experimental studies in the setting of secondary prophylaxis excluded patients with HCC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , while other studies have excluded only patients with advanced HCC [26] [27] [28] or HCC outside of the Milan criteria 6, 29 . Therefore it is unclear whether or not secondary prophylaxis is useful in these patients. A recent study in patients admitted due to variceal bleeding demonstrated greater in-hospital mortality in those patients with HCC compared to patients without HCC 9 . However this study was performed on a large database, based on ICD-9 diagnosis, with the limitations these studies have. Given the lack of information, the management of the acute variceal bleeding episode and then the use of secondary prophylaxis in these patients is most likely very heterogeneous across different centers. This gap in knowledge is becoming increasingly relevant given the rising incidence of HCC, mainly associated to viral cirrhosis, which is expected to peak within the next 10 years 30 . Therefore, the aim of this study was to evaluate the management and long term outcomes, as defined by rebleeding and death, of patients with HCC and esophageal variceal bleeding in comparison to patients without HCC.
PATIENTS AND METHODS
This retrospective observational study was performed in 10 centers in Spain Follow-up of all patients was prolonged until June 2011. Patients who received liver transplantation during the follow-up were censored at this time point. Data regarding the demographics, the liver disease, the bleeding episode and the follow-up were registered.
In the patients with HCC, information regarding the tumoral disease was collected.
Bleeding was considered from esophageal variceal origin when the emergency endoscopy, performed within 12 hours after admission, showed any of the accepted criteria defining variceal bleeding 31 . Baveno V definition of events associated to the bleeding episode were used: failure to control bleeding, six week rebleeding, six week death and failure of secondary prophylaxis, which includes any significant bleeding due to portal hypertension after day 5 during the complete follow-up, that leads to hospitalization, drop in 3 gr of hemoglobin, blood transfusion or death within six weeks of the rebleeding episode 32 . Previous decompensation was defined by the presence of ascites, hepatic encephalopathy or variceal bleeding.
Statistical Analysis.
Parametric and non parametric variables are described with means (SD) and medians (IQR) respectively. Categorical variables are described with proportions. Expectedly, viral etiology was proportionally more frequent among patients with HCC than in the control patients. Furthermore they had more frequently had previous decompensation than the control group (73% vs 60%, p=0.025). This finding was observed despite the fact that patients were matched by Child-Pugh class and had comparable MELD scores. Finally, HCC patients had more frequently portal vein thrombosis than control patients. Most patients had not had previous variceal bleeding and were eligible for primary prophylaxis (96 in HCC patients, 111 in non HCC patients). From these patients, 44 (43%) patients with HCC had primary prophylaxis compared to 40 (36%) patients without HCC (p=0.186). Similarly, from the patients who were eligible for secondary prophylaxis, no significant differences were observed between patients with HCC 37/44 (84%) vs patients without HCC 30/34 (88%) (p=0.755).
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Management and outcomes of variceal bleed.
No differences were observed regarding clinical presentation, endoscopic findings and initial pharmacological and endoscopic treatment ( Table 2) . Five-day failure was similar (25% and 18% in patients with and without HCC, p=0.257), although more patients with HCC died in this time period (11% vs 4 %, p=0.025). Within the first 6 weeks, HCC patients had greater rebleeding rate (17% vs 7%, respectively, p=0.022) and mortality (30% vs 15%, p=0.003). Significantly fewer HCC patients received secondary prophylaxis after bleeding (83% vs 93%, p=0.015) and, among those who received prophylaxis, standard therapy (combination of drugs and EBL) was used less frequently (59% vs 70%, p=0.098). As expected, patients with greater BCLC stages (C and D) had less frequently secondary prophylaxis (47/71, 66 %), while almost all patients with lower BCLC stages (0, A and B) had secondary prophylaxis (55/57, 96%, p<0.001). Overall, lack of secondary prophylaxis was significantly associated to 6 week rebleeding (25% of those without prophylaxis compared to 9% of patients with prophylaxis, p=0.016) and mortality (59% of those without prophylaxis compared to 8% of patients with prophylaxis, p<0.001). Portal vein thrombosis (none, benign, malignant respectively) was not associated to 5 day failure (20%, 24%, 30%, p=0.385) , although it was associated to 5 day mortality (5%, 0% and 23%, p<0.001) and 6 week rebleeding (8%, 7%, 29%, p=0.001).
Long term outcomes
No significant differences in rebleeding after 6 weeks were observed between patients with and without HCC (19% Vs 17%), p=0.714) (Table 3) . However, overall failure of secondary prophylaxis was more frequent in patients with HCC than controls (32% Vs 21%, p=0.05). Expectedly, lack of secondary prophylactic measures was associated with secondary prophylaxis failure (data not shown, p<0.001). Similarly, portal vein thrombosis was associated with secondary prophylaxis failure (None 25%, benign 21%, malignant Given the uneven distribution of well known prognostic markers of rebleeding and death, multivariate analysis was performed to evaluate the adjusted effect of HCC on survival (Table 4A) . Even when considering the other variables, HCC and lack of secondary prophylaxis remained independent predictors of death.
Stratified analysis was performed to evaluate specifically the effect of use of secondary prophylaxis in patients according to BCLC. In patients with a BCLC 0, A and B, most patients had secondary prophylaxis. However lack of secondary prophylaxis was associated to death (log rank <0.001) with a median survival of 0.9 months in patients without prophylaxis (2/57, 4 %), compared to 22 months in patients with prophylaxis 55/57, 96 %). Similarly in patients BCLC C and D, and despite their dismal prognosis, lack of secondary prophylaxis was also associated to death (log rank <0.001)) with a median survival 0.7 months (24/71, 34%), compared to 3 months in patients who had secondary prophylaxis (47/71, 66%) (figure 4).
A second model was performed in order to analyse the predictors of death in the subpopulation of patients with HCC and specifically the impact of the use of secondary prophylaxis taking into account BCLC classification stage. In this multivariate analysis
Child-Pugh score, portal vein thrombosis, BCLC classification and use of secondary prophylaxis remained independent predictors of death (Table 4B) 
DISCUSSION
In this study, a significantly lower survival rate was observed in patients who had HCC at the time of bleeding than patients who did not have HCC, despite the fact that the patients were matched for Child-Pugh class and age. This issue is of utmost interest as many studies that evaluated the treatment of acute bleeding episode and prophylaxis of rebleeding had excluded patients with HCC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Furthermore, given the increasing .
Interestingly patients with HCC were less likely to have secondary prophylaxis than patients without HCC and a trend for a less frequent use of standard secondary prophylaxis with combination of betablockers and endoscopic band ligation in those patients with HCC. The reason why HCC patients were not offered standard therapy is unclear from this study. It is likely that this was due to the assumption by the attending physician that this would not result in a clinical benefit. This is also suggested by the fact that patients with HCC without secondary prophylaxis seemed to have more severe liver disease. However, as lack of secondary prophylaxis was associated to a greater probability of failure and death in models adjusted for severity of liver disease, our results support offering patients with HCC the same treatment after variceal bleeding as it is done for patients without HCC. Although there were no differences in rebleeding rate after 6 weeks when comparing HCC to non-HCC patients, more patients with HCC died in this time period. Indeed, most patients with HCC who died, died of progressive tumoral disease and decompensated liver disease. In addition, when the specific predictors of failure of secondary prophylaxis and death were evaluated in patients with HCC including BCLC classification, the use of secondary prophylaxis had an independent protective effect on the development of rebleeding and death, further suggesting that use of this treatment should be prolonged as long as the clinical condition of the patient allows it.
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Hepatology Hepatology 13 Despite the fact that the groups were matched by Child-Pugh class and had similar MELD score, patients with HCC had more frequently previous decompensation than patients without HCC. Belonging to the compensated or decompensated phase of the liver disease is of utmost relevance given the well known survival differences between these groups 2 . Indeed, after introduction of MELD score, it had been remarked that different survival rates could be seen in patients with the same MELD score according to the presence or absence of clinical decompensation 38 . In the present study, it should be underlined that from the moment they experience variceal bleeding, all patients are in the There are several setbacks to the study. Some patients with very advanced HCC and upper gastrointestinal bleeding were not included in the study as no endoscopy was performed. This could lead to some bias in the results, as it is probable that these patients who were not included would be the ones who would be most likely to die. However, the decision to exclude these patients from the study was based on several reasons. Firstly, although suspected, the cause of the bleeding was not proven as endoscopy was not performed. It is well established that about one third of upper gastrointestinal bleeding episodes in patients with cirrhosis are due to other causes rather than esophageal varices 40, 41 . Secondly, most likely the patients who would not receive endoscopy would probably be the sickest ones and therefore with the most dismal outcome. Therefore inclusion of these patients in the analysis might further enhance the differences in the outcomes of variceal bleeding in patients with and without HCC. Furthermore, and although it seems that patients with HCC without secondary prophylaxis were more sick than the ones who received secondary prophylaxis,which may have influenced the physicians opinion, it could be that there are other factors that influenced this decision that are not included in the analysis. Unfortunately, the study design does not allow analysis of the impact of sorafenib treatment on variceal bleeding. It has been establshed both in animal and human studies that sorafenib has a portal hypotensive effect, perhaps through an inhibition of angiogenesis 42, 43 . Therefore, there could be an impact of the administration of this drug on the outcomes. In the present study, sorafenib was administered exclusively to patients with advanced HCC, therefore it is logical to speculate that lack of sorafenib could further worsen the outcome of these patients, who already have a dismal prognosis.
Another limitation of the study is the uneven distribution of the etiologies among patients with and without HCC. Although on multivariate analysis viral disease was not identified as an independent predictor of death (and therefore non-viral disease, which was mainly alcohol, was not identified as a predictor of survival), it could be that non-HCC patients with alcoholic liver disease ceased alcohol consumption after the variceal bleed and therefore had a better outcome. Finally, the design of this study does not allow evaluation of the impact of variceal bleeding in the natural history of HCC.
In conclusion patients with HCC with variceal bleed have worse outcomes than patients without HCC. These differences are only partially explained by differences in secondary prophylaxis measures, as in patients with variceal hemorrhage and HCC. Use of secondary prophylaxis has survival benefit in patients with HCC irrespective of BCLC stage. 
